Bosentan and Pulmonary Endothelial Function

• Status: Completed
• Trial end date: 2009-12-01
• Target enrollment: 0
• Participant gender: All

Summary

6 months therapy of Bosentan, an endothelin antagonist, will lead to improvement in pulmonary microvascular endothelial function.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Prof David S Celermajer
• Treatments: Bosentan

Criteria

Inclusion Criteria:

• Pulmonary arterial hypertension; idiopathic and connective tissue disease associated

• Confirmed or invasive haemodynamic:

• Mean pulmonary arterial pressure greater than or equal to 25 millimeters of mercury

• Pulmonary capillary wedge pressure less than 15 millimeters of mercury

• No prior pulmonary hypertension specific therapy

• Ability to provide informed consent

Exclusion Criteria:

• Contra-indications to medications used to test endothelial function; acetylcholine, sodium nitroprusside, NG-Monomethyl-L-Arginine, L-arginine

• Advanced renal disease

• Previous allergic reaction to contrast agents